TIMOGLOBULINA 5 mg/ml clinical trials

MULTICENTER, RANDOMIZED STUDY TO EVALUATE THE EFFICACY OF INDIVIDUALIZATION OF IMMUNOLOGICAL RISK BASED ON SELECTIVE BIOMARKERS (HLA EPLETH DISPARITY AND IFN-γ ELISPOT) TO OPTIMIZE IMMUNOSUPPRESSIVE TREATMENT IN LIVING DONOR KIDNEY TRANSPLANT PATIENTS (BIOIMMUN)

This study looks at how to best adjust medicines after a kidney transplant from a living donor. It aims to find the right amount of medicine for each patient to prevent their body from rejecting the new kidney, using special tests to guide treatment.